Advertisement
Mayo Clinic Proceedings Home
MCP Digital Health Home

Treatment Considerations for Patients With Neuropathic Pain and Other Medical Comorbidities

      The efficacy of drugs for neuropathic pain has been established in randomized controlled trials that have excluded patients with comorbid conditions and those taking complex medications. However, patients with neuropathic pain frequently present with complex histories, making direct application of this evidence problematic. Treatment of neuropathic pain needs to be individualized according to the cause of the pain, concomitant diseases, medications, and other individual factors. Tricyclic antidepressants (TCAs), gabapentinoids, selective noradrenergic reuptake inhibitors, and topical lidocaine are the first-line choices; if needed, combination therapy may be used. When a new drug is added, screening for potential drug interactions is recommended. The TCAs have anticholinergic adverse effects and may cause orthostatic hypotension. They should be avoided or used cautiously in patients with cardiac conduction disturbances or arrhythmias. Patients who lack cytochrome P450 2D6 isoenzyme activity are prone to adverse effects of TCAs and venlafaxine and have a weaker analgesic response to tramadol. A combination of several serotoninergic drugs may lead to serotonin syndrome. Risk of gastrointestinal tract bleeding is increased in patients taking selective serotonin reuptake inhibitors or venlafaxine, especially when combined with nonsteroidal anti-inflammatory drugs. Dose adjustment may be needed in patients with renal or hepatic impairment. Depending on the drug, the dose is reduced or the dosage interval lengthened. Slow titration and careful follow-up are needed. No drug is absolutely safe during pregnancy and lactation. Particular care must be exercised during the first trimester when drug dose should be as low as possible. Individual weighing of benefits and risks should guide therapeutic decisions.
      ADR (adverse drug reaction), BP (blood pressure), CKD (chronic kidney disease), CYP (cytochrome P450), ECG (electrocardiogram), EM (extensive metabolizer), GFR (glomerular filtration rate), MI (myocardial infarction), NP (neuropathic pain), NSAID (nonsteroidal anti-inflammatory drug), OR (odds ratio), PM (poor metabolizer), RCT (randomized controlled trial), SNRI (selective noradrenergic reuptake inhibitor), TCA (tricyclic antidepressant), UM (ultrarapid metabolizer)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Treede RD
        • Jensen TS
        • Campbell JN
        • et al.
        Neuropathic pain: redefinition and a grading system for clinical and research purposes.
        Neurology. 2008; 70: 1630-1635
        • Smith BH
        • Torrance N
        • Bennett MI
        • Lee AJ
        Health and quality of life associated with chronic pain of predominantly neuropathic origin in the community.
        Clin J Pain. 2007; 23: 143-149
        • Bouhassira D
        • Lanteri-Minet M
        • Attal N
        • et al.
        Prevalence of chronic pain with neuropathic characteristics in the general population.
        Pain. 2008; 136: 380-387
        • Freynhagen R
        • Baron R
        • Gockel U
        • Tölle TR
        painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain.
        Curr Med Res Opin. 2006; 22: 1911-1920
        • Daousi C
        • MacFarlane IA
        • Woodward A
        • et al.
        Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes.
        Diabet Med. 2004; 21: 976-982
        • Davies M
        • Brophy S
        • Williams R
        • Taylor A
        The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes.
        Diabetes Care. 2006; 29: 1518-1522
        • Kehlet H
        • Jensen TS
        • Woolf CJ
        Persistent postsurgical pain: risk factors and prevention.
        Lancet. 2006; 367: 1618-1625
        • Jensen MP
        • Chodroff MJ
        • Dworkin H
        The impact of neuropathic pain on health-related quality of life: review and implications.
        Neurology. 2007; 68: 1178-1182
        • Argoff CE
        The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach.
        Clin J Pain. 2007; 23: 15-22
        • Cruccu G
        • Aziz L
        • Garcia-Larrea L
        • et al.
        EFNS guidelines on neurostimulation therapy for neuropathic pain.
        Eur J Neurol. 2007; 14: 952-970
        • Attal N
        • Cruccu G
        • Haanpää M
        • et al.
        EFNS guidelines on pharmacological treatment of neuropathic pain.
        Eur J Neurol. 2006; 13: 1153-1169
        • Dworkin RH
        • O'Connor A
        • Backonja M
        • et al.
        Pharmacologic management of neuropathic pain: evidence-based recommendations.
        Pain. 2007; 132: 237-251
        • Gilron I
        • Watson CPN
        • Cahill CM
        • Moulin DE
        Neuropathic pain: a practical guide for the clinician.
        CMAJ. 2006; 175: 265-275
        • Moulin DE
        Opioid analgesics in the management of neuropathic pain.
        Eur J Pain. 2007; 1: 57-60
        • Virani A
        • Mailis A
        • Shapiro LE
        • Shear NH
        Drug interactions in human neuropathic pain pharmacotherapy.
        Pain. 1997; 73: 3-13
        • Gilron I
        • Bailey JM
        • Tu D
        • et al.
        Morphine, gabapentin, or their combination for neuropathic pain.
        N Engl J Med. 2005; 352: 1324-1334
        • Hanna M
        • O'Brien C
        • Wilson MC
        Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients.
        Eur J Pain. 2008; 12: 804-813
        • Gatti A
        • Sabato AF
        • Ochhioni R
        • et al.
        Controlled-release oxycodone and pregabalin in the treatment of neuropathic pain: results of a multicenter Italian study.
        Eur Neurol. 2009; 61: 129-137
        • Gilron I
        • Bailey JM
        • Tu D
        • et al.
        Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.
        Lancet. 2009; 374: 1252-1261
        • Graff-Radford SB
        • Shaw LR
        • Naliboff BN
        Amitriptyline and fluphenazine in the treatment of postherpetic neuralgia.
        Clin J Pain. 2000; 16: 188-192
        • Khoromi S
        • Cui L
        • Nackers L
        • Max MB
        Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain.
        Pain. 2007; 130: 66-75
        • Walker JM
        • Farney RJ
        • Rhondeau SM
        • et al.
        Chronic opioid use is a risk factor for the development of central sleep apnea and ataxic breathing.
        J Clin Sleep Med. 2007; 3: 455-461
        • Webster LR
        • Choi Y
        • Desai H
        • Webster L
        • Grant BJ
        Sleep-disordered breathing and chronic opioid therapy.
        Pain Med. 2008; 9: 425-432
        • Zhang M
        • Holman CD
        • Price SD
        • Sanfilippo FM
        • Preen DB
        • Bulsara MK
        Comorbidity and repeat admission to hospital for adverse drug reactions in older adults: retrospective cohort study.
        BMJ. 2009; 338: a2752
        • Lazarou J
        • Pomeranz BH
        • Corey N
        Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.
        JAMA. 1998; 279: 1200-1205
        • SFINX Drug Interactions
        (Accessed January 11, 2010.)
        • Eckhardt K
        • Ammon S
        • Hofmann U
        • et al.
        Gabapentin enhances the analgesic effect of morphine in healthy volunteers.
        Anesth Analg. 2000; 91: 185-191
        • Mallet L
        • Spinewine A
        • Huang A
        The challenge of managing drug interactions in elderly people.
        Lancet. 2007; 370: 185-191
        • Bijl MJ
        • Visser LE
        • Hofman A
        • et al.
        Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants.
        Br J Clin Pharmacol. 2007; 65: 558-564
        • Kirchheiner J
        • Keulen JT
        • Bauer S
        • Roots I
        • Brockmöller J
        Effects of the CYP2D6 gene duplication on the pharmacokinetics and pharmacodynamics of tramadol.
        J Clin Psychopharmacol. 2008; 28: 78-83
        • Gasche Y
        • Daali Y
        • Fathi M
        • et al.
        Codeine intoxication associated with ultrarapid CYP2D6 metabolism.
        N Engl J Med. 2004; 351: 2827-2831
        • Shams MEE
        • Arneth B
        • Hiemke C
        • et al.
        CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
        J Clin Pharm Ther. 2006; 31: 493-502
        • Goetz MP
        • Kamal A
        • Ames MM
        Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
        Clin Pharmacol Ther. 2008; 83: 160-166
        • Boyer EW
        • Shannon M
        The serotonin syndrome.
        N Engl J Med. 2005; 352: 1112-1120
        • de Abajo FJ
        • García-Rodríguez LA
        Risk of upper gastrointestinal track bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with non-steroidal anti-inflammatory drugs and effect of acid-suppressing agents.
        Arch Gen Psychiatry. 2008; 65: 795-803
        • Penning-van Beest F
        • Erkens J
        • Petersen KU
        • Koelz HR
        • Herings R
        Main comedications associated with major bleeding during anticoagulant therapy with coumarins.
        Eur J Clin Pharmacol. 2005; 61: 439-444
        • Jiang W
        • Davidson JRT
        Antidepressant therapy in patients with ischemic heart disease.
        Am Heart J. 2005; 150: 871-881
        • Ray WA
        • Griffing MR
        • Malcom E
        Cyclic antidepressants and the risk of hip fracture.
        Arch Intern Med. 1991; 151: 754-756
        • Hubbard R
        • Farrington P
        • Smith C
        • Smeeth L
        • Tattersfield A
        Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture.
        Am J Epidemiol. 2003; 158: 77-84
        • Reilly JG
        • Ayis SA
        • Ferrier IN
        • Jones SJ
        • Thomas HL
        QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.
        Lancet. 2000; 355: 1048-1052
        • Cohen HW
        • Gibson G
        • Alderman MH
        Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents.
        Am J Med. 2000; 108: 2-8
        • Hippisley-Cox J
        • Pringle M
        • Hammersley V
        • et al.
        Antidepressants as risk factor for ischaemic heart disease: case-control study in primary care.
        BMJ. 2001; 323: 666-669
        • Tata LJ
        • West J
        • Smith C
        • et al.
        General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction.
        Heart. 2005; 91: 465-471
        • Ray WA
        • Meredith S
        • Thapa BP
        • Hall K
        • Murray KT
        Cyclic antidepressants and the risk of sudden cardiac death.
        Clin Pharmacol Ther. 2004; 75: 234-241
        • Johnson EM
        • Whyte E
        • Mulsant BH
        • et al.
        Cardiovascular changes associated with venlafaxine in the treatment of late-life depression.
        Am J Geriatr Psychiatry. 2006; 14: 796-802
        • Page II, RL
        • Cantu M
        • Lindenfeld J
        • Hergott LJ
        • Lowes BD
        Possible heart failure exacerbation associated with pregabalin: case discussion and literature review.
        J Cardiovasc Med (Hagerstown). 2008; 9: 922-925
      1. Lyrica® (pregabalin) [package insert]. Pfizer, New York, NY2006 Apr
        • Krantz MJ
        • Martin J
        • Stimmel B
        • Mehta D
        • Haigney MCP
        QTc interval screening in methadone treatment.
        Ann Intern Med. 2009; 150: 387-395
        • Levey AS
        • Eckardt KU
        • Tsukamoto Y
        • et al.
        Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
        Kidney Int. 2005; 67: 2089-2100
        • Coresh J
        • Selvin E
        • Stevens LA
        • et al.
        Prevalence of chronic kidney disease in the United States.
        JAMA. 2007; 298: 2038-2047
        • Harris K
        • Stribling B
        Automated estimated GFR reporting: a new tool to promote safer prescribing in patients with chronic kidney disease?.
        Ther Clin Risk Manag. 2007; 3: 969-972
        • Munar MY
        • Singh H
        Drug dosing adjustments in patients with chronic kidney disease.
        Am Fam Physician. 2007; 75: 1487-1496
        • Verbeeck RK
        Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.
        Eur J Clin Pharmacol. 2008; 64: 1147-1161
        • Einarson A
        Risks/safety of psychotropic medication use during pregnancy.
        Can J Clin Pharmacol. 2009; 16: e58-e65
        • Buhimschi CS
        • Weiner CP
        Medications in pregnancy and lactation: part 1, teratology.
        Obstet Gynecol. 2009; 113: 166-188
        • Althshuler LL
        • Cohen L
        • Szuba MP
        • Burt VK
        • Gitlin M
        • Mintz J
        Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
        Am J Psychiatry. 1996; 153: 592-606
        • Einarson A
        • Fatoye B
        • Sarkar M
        • et al.
        Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study.
        Am J Psychiatry. 2001; 158: 1728-1730
        • Lennestål R
        • Källén B
        Delivery outcome in relation to maternal use of some recently introduced antidepressants.
        J Clin Psychopharmacol. 2007; 27: 607-613
        • Menon SJ
        Psychotropic medication during pregnancy and lactation.
        Arch Gynecol Obstet. 2008; 277: 1-13